NCT02835833View on ClinicalTrials.gov

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 9, 2016

Primary Completion Date

April 14, 2018

Study Completion Date

June 14, 2018

Conditions
Renal Cell CarcinomaColorectal AdenocarcinomaNon-squamous Non-small Cell Lung CancerPlatinum-refractory Ovarian CarcinomaCervical Carcinoma
Interventions
DRUG

Nintedanib

Nintedanib will be given twice daily at either 150 mg or 200 mg.

DRUG

Bevacizumab

Bevacizumab will be given at 15 mg/kg

Trial Locations (1)

35294

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT02835833 - Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter